Tagged with USA,

USA Peter Marks, director of the US FDA’s Center for Biologics Evaluation and Research, outlines how the organization is attempting to further promote the advancement of cutting edge cell and gene therapies in the US and beyond.   To keep pace with the remarkable and continuing growth of gene therapy, FDA’s…

USA The AAM’s Chip Davis examines the roadblocks to greater adoption of biosimilar drugs in the USA, and why they need to be removed to potentially save billions of dollars and increase patient access to lifesaving medications.     In a nutshell: competition brings prices down across the board Biologic drugs…

USA AstraZeneca’s Rick R. Suarez looks at workable solutions to the challenges facing healthcare in the US and why inter-stakeholder collaboration, rather than finger-pointing, is the only way forward.   Discussion and debate related to cost and quality in healthcare has never been more pronounced or more contentious, whether focusing on…

USA BioNJ’s president and CEO Debbie Hart reflects on the association’s mission of creating a robust and engaging life sciences ecosystem in New Jersey. Hart also outlines how BioNJ is hoping to continue to grow the region’s reputation as a hub that stands out for its level of expertise, favourable geographic…

USA Carla Smith looks at the various cybersecurity risks that exist across the US healthcare continuum and the steps that executive leadership can take to combat this threat.   Keeping patient data safe and secure remains a challenge. Thanks to a 9-year review of experiences in the United States, we know…

USA The US drug-price watchdog, The Institute for Clinical & Economic Review (ICER) recently issued a “Report on Unsupported Price Increases,” picking a number of innovative medicines that it says have seen price hikes without sufficient substantiation. While the study made the headlines, Certara’s Ulrich Neumann calls for some scepticism and…

UAE The UAE is putting a greater emphasis on healthcare than ever before as part of its ‘Vision 2021’ model. With the aim of being “flexible in adopting new economic models and capitalizing on global economic partnerships,” the Emirates are seeing greater numbers of investments and partnerships in healthcare, many of…

Opinion Sophia Ononye outlines the history of cannabis as a medicine in the US and, following the first FDA approval of a cannabis-derived drug product in 2018, the highly promising landscape for further approvals.   The landscape for approved CBD products is highly promising and will undoubtedly lead to additional FDA…

USA Although Boston and California may be more internationally renowned as biotech hubs, New York is fast catching up. Thanks in large part to its strong scientific and business infrastructure and easy access to capital, growing numbers of early-stage biotechs are choosing to base their operations in New York and list…

USA Jennifer Hawks Bland of NewYorkBIO, the premier trade association for the life sciences in New York State, discusses the association’s diverse list of members, the services it provides them, and how New York is building a bio-ecosystem to rival those of Boston and California.   We have the unique ability…

Opinion Krishna Cheriath, chief data officer at BMS, outlines the ways in which AI is already transforming the delivery of healthcare, what modern biopharma companies’ AI innovation agendas should include, and why behavioural change is a key tenet in securing meaningful health outcomes with AI.   As Biopharma increases AI investments,…

USA In the face of rising costs in American healthcare, Carla Smith outlines five ways in which the US can improve the financial sustainability of its healthcare system.   Let’s take advantage of systems-level expertise and change our reality for the better In the United States, 18 percent of the gross…